Patients with high-risk acute myelogenous leukemia (AML) in first remission are at increased risk for disease recurrence and are often considered for allogeneic bone marrow transplantation (BMT) if there is a suitable HLA-identical sibling donor. Analysis of results from randomized clinical trials comparing different treatment strategies for patients with AML (chemotherapy, autologous BMT, and allogeneic BMT) suggests that allogeneic BMT may be a superior treatment modality for patients in the high-risk subgroup. Interpretation of clinical trial results, however, is problematic due to poor compliance with transplant options, absence of studies specifically designed to addresses this question, and ongoing redefinition of the highrisk subgroup. Alternative allogeneic transplant approaches to reduce toxicity from graft-versus-host disease and enhance graft-versus-leukemia reactivity may offer therapeutic promise in this patient population.
The response of patients with acute myelogenous leukemia (AML) to therapeutic modalities such as chemotherapy or bone marrow transplantation (BMT) has been shown to be highly dependent upon disease characteristics present at the time of diagnosis. One of the most powerful prognostic indicators is the cytogenetic profile, which is now utilized by most investigators to stratify patients at varying risks of disease recurrence. [1] [2] [3] [4] [5] Patients with adverse cytogenetic profiles have been shown to have an extremely poor prognosis, with survival rates ranging between 15 and 20%. Many of these patients are considered for allogeneic BMT if they have suitable donors. A central question, however, is whether allogeneic BMT is superior treatment for this patient population relative to other therapeutic modalities, such as intensive consolidation chemotherapy or autologous bone marrow/peripheral stem cell transplantation.
Results of large clinical trials for patients with high-risk AML
There have been five cooperative group trials in which the role of allogeneic BMT in patients with AML in first remission has been comparatively examined relative to other therapeutic options noted above. 3, [6] [7] [8] [9] [10] [11] The basic trial designs of these studies were similar with few exceptions (Figure 1 ). For example, the US Intergroup study randomized patients after induction without any antecedent consolidation, and the EORTC/GIMEMA AML 10 trial randomized patients to transplant options only. All trials enrolled a large number of patients with similar age ranges. Three of the studies used cytogenetics to define high-risk disease while two (eg, EORTC AML 8 and GOELAM) employed presenting white cell count and FAB subtype to delineate a high-risk population. All of the trials used the intent-to-treat population as the basis for statistical analysis. Notably, the US Intergroup trial was the only one in which patients randomized to receive autologous transplantation or chemotherapy were stratified by cytogenetics. Additionally, patients in the MRC AML 10 trial also included patients with secondary AML and myelodysplastic syndromes.
While the purpose of these trials was to assess the efficacy of assigned treatment modalities in all enrolled patients with AML, subgroup analysis of patients with favorable, intermediate, and unfavorable disease was performed in each of these studies. Three trials used a donor/no donor analysis in an effort to reduce bias due to patient dropout. In the two remaining trials, the allogeneic BMT arm was compared to a combined group of patients who received either autologous BMT or chemotherapy. Subgroup analysis of overall survival for high-risk patients revealed no difference in survival between patients randomized to allogeneic BMT vs autologous BMT and/or chemotherapy in either the MRC AML10, EORTC/ GIMEMA AML8 or GOELAM trials (Table 1) . Conversely, both the US Intergroup and the EORTC/GIMEMA AML 10 trials showed survival advantages for allogeneic BMT, although P-values in both instances were marginal.
Limitations of clinical trial data
Despite the large number of enrolled patients, there are a number of limitations that exist in all of the trials. First of all, randomization to the allogeneic BMT arm in each of the trials was 'genetic' in that it was based on the availability of an HLA-identical sibling donor. There have been no studies in which patients with HLA-identical sibling donors were randomized to either receive or not receive allogeneic BMT. Secondly, the expressed purpose of the trials was to examine outcome in all AML first-remission patients enrolled in the study, and not just high-risk patients. Therefore, the subgroup analyses performed for high-risk patients involved small numbers of patients and were underpowered to detect small differences. Of note, the EORTC/GIMEMA AML 10 Trial, which showed a survival advantage for recipients of allografts, had the largest patient population with poor-risk AML. Thirdly, stratification for high-risk features was not performed in any of the trials prior to enrollment, which may have introduced biases that could have affected survival outcomes. A recent study by the German AML Leukemia group performed such an upfront stratification for prognostic features in patients prior to randomization. 12 In the high-risk arm, in which patients were randomized to receive allogeneic BMT or autologous BMT, however, only a small number of patients actually received the assigned therapy, again reflecting one of the obstacles intrinsic to this type of analysis. Fourthly, all of the clinical trials have been characterized by lack of compliance with the assigned treatment. 13 As shown in Table 2 , only 70% of patients in four of the large studies actually received an HLAidentical sibling transplant. Moreover, less than 50% of patients available for randomization to autologous BMT or conventional chemotherapy were randomized and less than 70% of patients assigned to receive autografts actually received them. Compliance with chemotherapy has tended to be much better, but overall these studies reflect the substantial patient dropout that occurs in these trials. The inherent problem with poor compliance is that it can result in underestimation of both the potential efficacy and toxicity of a specific treatment. Finally, there continues to be ongoing redefinition of AML risk groups. For example, patients with normal cytogenetics are typically placed within an intermediate prognostic group. However, recent studies by a number of investigators have identified abnormalities such as FLT3 internal tandem duplications, 14 partial tandem duplications of the MLL gene, 15 and high expression of BAALC 16 that appear to confer adverse prognosis on overall survival and disease recurrence in AML patients with otherwise normal cytogenetics. How redistribution of these patients to the highrisk AML subset would affect survival outcome of transplant and nontransplant-based therapeutic strategies is uncertain.
Alternative approaches to the treatment of high-risk AML using allogeneic transplantation
Existing clinical trial data have analyzed the role of HLAidentical sibling BMT in comparison to other treatment modalities. This raises the question as to whether there are any alternative allogeneic BMT approaches that have been examined for patients with high-risk AML. Table 3 lists several alternative strategies that might be considered for patients with poor prognosis disease. One is the use of ex vivo T-cell depletion (TCD). A potential advantage of using TCD is that the major complication of allogeneic BMT is transplant-related mortality that is primarily attributable to graft-versus-host disease (GVHD). Since TCD has been shown to reduce the incidence and severity of GVHD, there exists the potential to reduce transplant-related mortality and improve overall survival in this patient cohort. While there have been no randomized studies that have compared transplantation of TCD vs non-TCD marrow grafts, data available from the International Bone Marrow Transplant Registry (IBMTR) have shown no overall difference in survival after HLA-identical sibling transplantation for patients with high-risk AML, albeit with limited numbers of patients (M Horowitz, personal communication).
An alternative approach is to consider the use of matched unrelated marrow grafts in an effort to enhance the graft-versusleukemia (GVL) effect due to the likelihood for increased minor histocompatibility antigenic disparity between donor and recipient in patients receiving unrelated vs HLA-identical sibling marrow grafts. Data from the IBMTR, again in a limited number of patients, show no difference in overall survival between these two patient groups (M Horowitz, personal communication). Moreover, when one examines the risk of disease recurrence, where a favorable effect for unrelated marrow grafts would be postulated to occur, there is no difference in the probability of disease recurrence.
A more recent and intriguing area of investigation has been the use of killer inhibitory receptor (KIR) incompatibility to augment the GVL effect in allogeneic stem cell transplant recipients. Natural killer (NK) cells express KIRs that are clonally distributed on NK cell populations. 17 These cells recognize ligands on recipient targets. Some of these target antigens have been identified and found to consist of selected HLA-B and HLA-C alleles. When the appropriate KIR recognizes its ligand, no killing of the target cell is observed. Conversely, when a donor NK cell KIR does not recognize the appropriate ligand, the recipient target cell can be killed. Investigators in Perugia AML trial study designs. Abbreviations: Allo, allogeneic; AML, acute myelogenous leukemia; Auto, autologous; BM, bone marrow; ICC, intensive consolidation chemotherapy; PBSC, peripheral blood stem cell; Rx, therapy. demonstrated that patients with advanced AML had a statistically significant improvement in overall survival after haploidentical stem cell transplantation if there was a KIR incompatibility in the graft-versus-host direction. The basis for the improved survival was a substantial decrease in relapse rate reflecting a GVL effect conferred presumably by NK cells reconstituting in the recipient and able to recognize and eliminate leukemia cells. It should be emphasized that the majority of these patients had advanced AML and not AML in first remission. Nonetheless, the fact that patients with high-risk AML in first remission are still at substantial risk for disease recurrence suggests that this strategy may be worthy of investigation in this patient population to determine if overall survival can be improved. Peripheral stem cell transplantation using HLA-identical sibling donors is being increasingly used in place of BMT to treat patients with hematologic malignancies. Several randomized studies have shown a survival advantage for patients with advanced leukemia receiving peripheral stem cell as opposed to bone marrow grafts. 19, 20 Such a finding, however, has not been observed for patients with 'good-risk' disease. Patients with high-risk AML in first remission are typically placed into the good risk group and therefore the relative value of peripheral stem cells has not yet been addressed. A recent study by Gorin et al 21 retrospectively analyzed 881 patients with AML in first remission who underwent allogeneic transplantation; 515 patients received bone marrow grafts and 366 peripheral stem cell products. All patients received stem cell grafts from HLAidentical sibling donors. The purpose of this study was to compare transplant outcomes in those patients who received low-dose bone marrow cell inoculums (defined as being less than the median of 2.7 Â 10 8 cells/kg) compared to those who received high-dose bone marrow cell inoculums or those receiving peripheral stem cell products. Notably, less than 10% of these patients had high-risk AML in first remission. Results of this study demonstrated a statistically significant survival advantage for those patients receiving high-dose bone marrow vs either peripheral blood stem cells or low-dose bone marrow cell inoculums. Future studies, however, are needed to define whether or not use of peripheral stem cells vs bone marrow cells offers any survival advantage for patients with high-risk AML.
A final consideration is the use of nonmyeloablative stem cell transplantation. Recent data using a case-matched historical cohort analysis have shown that nonmyeloablative stem cell transplants may reduce regimen-related toxicity in older patients who are not suitable candidates for myeloablative regimens. 22 The use of nonmyeloablative stem cell transplantation, however, has not been similarly examined in younger patients. If this can be confirmed in prospective randomized studies, than this may offer another treatment approach to improve overall survival in high-risk AML patients.
Can this question be addressed short of a randomized clinical trial?
A major limitation to interpretation of clinical AML BMT trials has been the small number of patients available for subgroup analyses. One approach to address this problem is the use of meta-analysis, which allows for the compilation of clinical trial results from multiple sources in an effort to assess and quantify the relative value of a specific treatment modality. In BMT studies, this has been recently done for patients with AML receiving either autologous BMT or ongoing chemotherapy. 23 Results of this analysis showed no overall survival advantage for either approach. A similar analysis has also been performed in pediatric AML patients to evaluate the role of allogeneic BMT in first remission AML. 24 A criticism of this approach is that often the trial designs are not similar and observed outcomes for the same end point may exhibit substantial variability. To that end, some have argued for the use of individual patient data meta analysis in which one goes back to the source material as a more appropriate way to address this question. 25 
Summary
Available data indicate that allogeneic BMT appears to be no worse than other treatment approaches and may even be a superior treatment modality for adult patients with high-risk AML who have an HLA-identical sibling donor. Interpretation of clinical trial results, however, remains problematic due to poor compliance with transplant options, absence of studies specifically designed to address this question, and ongoing redefinition of risk groups that results in an ever-changing landscape of what constitutes high-risk disease. The potential role of alternative approaches such as nonmyeloablative stem cell transplantation, allogeneic peripheral blood stem cell trasnplantation, and exploitation of KIR incompatibility remain intriguing strategies that await further study.
